Gefurulimab  (Synonyms: ALXN-1720)

Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis^[1][2][3].

VH-VH'

C5 (complement 5, C5a anaphylatoxin)

727  [NCBI] & 728  [NCBI]

P01031 & P21730

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

28.17 kDa

2456407-94-4

Liquid

Colorless to light yellow

[Gefurulimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  VH-VH'

• [1]. Sandra Rayego-Mateos, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022 Dec 5:S0085-2538(22)01017-1.  [Content Brief]

  [2]. Mullin M, et al. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions. MAbs. 2024 Jan-Dec;16(1):2341443.  [Content Brief]

  [3]. Miwa T, et al. Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases. Annu Rev Med. 2024 Jan 29;75:189-204.  [Content Brief]